AVALYN PHARMA ($AVLN) posted quarterly earnings results for Q3 2026 on Thursday, November 12th. The company reported earnings of -$0.67 per share, beating estimates of -$0.73 by $0.06. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market open this morning: -2.42%
You can see Quiver Quantitative's $AVLN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AVALYN PHARMA Hedge Fund Activity
We have seen 97 institutional investors add shares of AVALYN PHARMA stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NOVO HOLDINGS A/S added 3,883,289 shares (+inf%) to their portfolio in Q2 2026, for an estimated $127,837,873
- SR ONE CAPITAL MANAGEMENT, LP added 3,308,649 shares (+inf%) to their portfolio in Q2 2026, for an estimated $108,920,725
- PERCEPTIVE ADVISORS LLC added 2,675,296 shares (+inf%) to their portfolio in Q2 2026, for an estimated $88,070,744
- NVP ASSOCIATES, LLC added 2,268,404 shares (+inf%) to their portfolio in Q2 2026, for an estimated $74,675,859
- WELLINGTON MANAGEMENT GROUP LLP added 2,201,986 shares (+inf%) to their portfolio in Q2 2026, for an estimated $72,489,379
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,735,231 shares (+inf%) to their portfolio in Q2 2026, for an estimated $57,123,804
- CATALIO CAPITAL MANAGEMENT, LP added 1,675,830 shares (+inf%) to their portfolio in Q2 2026, for an estimated $55,168,323
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AVALYN PHARMA Price Targets
Multiple analysts have issued price targets for $AVLN recently. We have seen 3 analysts offer price targets for $AVLN in the last 6 months, with a median target of $53.0.
Here are some recent targets:
- Judah Frommer from Morgan Stanley set a target price of $53.0 on 05/26/2026
- Seamus Fernandez from Guggenheim set a target price of $80.0 on 05/26/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $51.0 on 05/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.